A 2025 study found that tripling semaglutides dose to 7.2 mg led to roughly 19% weight loss over 72 weeks, compared to 16% at the standard dose, a meaningful gain, though with higher rates of side effects
Stop the medication and seek medical attention immediately
Cagrilintide targets the amylin receptor pathway, which complements GLP-1 mechanisms through different appetite regulation circuits
Fasting helps manage eating patterns and supports metabolic health, while semaglutide controls appetite and improves insulin sensitivity
In the 72-week SURMOUNT-1 trial summarised in Mounjaros Australian product information, average weight change ranged from -16.0% to -22.5% depending on dose, versus -2.4% with placebo
Zepbound KwikPen onlysingle-dose vials and single-dose pens not covered